Evidence map›Paper›PMID 41487569›Full record

ArticleFrontiers in oncology2025

Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report.

Maliha Nusrat, Kenneth H Yu, Laura Tang, Mohammad Ali El Amine, Brian McCarthy, Karuna Ganesh, Elisa de Stanchina, Emmanouil Pappou, Julio Garcia-Aguilar, Meredith Bartelstein and 4 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maliha NusratGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Kenneth H YuGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Laura TangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Mohammad Ali El AmineDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Brian McCarthyAdera Biolabs, Germantown, MD, United States.
Karuna GaneshGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Elisa de StanchinaThe Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Emmanouil PappouDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Julio Garcia-AguilarDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Meredith BartelsteinDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Christopher CraneDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
David KelsenGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Leonard SaltzGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Carla HajjDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Metastatic mucinous adenocarcinoma arising from a tailgut cyst is an ultra-rare cancer. Literature on the chemosensitivity and radiosensitivity of this cancer is lacking, and treatment is extrapolated from rectal cancer management. We are reporting, for the first time, the case of a patient with metastatic tailgut cyst adenocarcinoma who derived 1.5 years of clinical benefit from treatment with gemcitabine, selected as a result of transcriptomic analysis of her circulating tumor cells using an

Indexed as

chemosensitivity assaycirculating tumor cellspersonalized medicineretrorectal cyst hamartomatailgut cyst adenocarcinoma

Identifiers

PMID41487569
PMCPMC12756884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.